Ascletis Announces 3CLpro Inhibitor ASC11 Demonstrated Potential to be Effective Treatment for COVID-19 |
| April 19, 2022 | April 2022 Bond Updates |
|
- In antiviral cellular assays, antiviral potency (EC90) of ASC11 is 31-fold of that of Nirmatrelvir, 120-fold of that of S-217622, 16-fold of that of PBI-0451 and 7-fold of that of EDP-235. - ASC11 is an in-house discovered oral small molecule drug candidate, targeting 3CLpro, with... |
| View more at: https://www.prnewswire.com:443/news-releases/ascletis-announces-3clpro-inhibitor-asc11-demonstrated-potential-to-be-effective-treatment-for-covid-19-301527722.html |
| Related News |
|